Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SNCA | P37840 | 2/20 | 0.50 |
| ▸ | PTPRF | P10586 | 1/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CRHBP | P24387 | 2/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8374037 | 0.98 | CYP1A2 (0.53) | CYP1A2CYP2C19ALDH1A1SNCAPTPRF | |
| Bromide SCHEMBL722749 | 0.97 | SNCA (0.53) | CYP1A2CYP2C19ALDH1A1SNCAPTPRF | |
| SCHEMBL8379641 | 0.92 | CYP1A2 (0.47) | CYP1A2CYP2C19ALDH1A1SNCAPTPRF | |
| SCHEMBL8374699 | 0.92 | CYP1A2 (0.47) | CYP1A2CYP2C19ALDH1A1SNCAPTPRF | |
| SCHEMBL8379642 | 0.85 | SNCA (0.44) | CYP1A2CYP2C19ALDH1A1SNCAPTPRF | |
| SCHEMBL2085893 | 0.83 | SNCA (0.53) | CYP1A2CYP2C19ALDH1A1SNCALMNA | |
| Hydrochloric Acid SCHEMBL7117545 | 0.82 | TSHR (0.54) | CYP1A2CYP2C19ALDH1A1LMNAMEN1 | |
| Bromide SCHEMBL5828742 | 0.81 | LMNA (0.44) | CYP1A2CYP2C19ALDH1A1SNCAPTPRF | |
| Hydrochloric Acid SCHEMBL2446696 | 0.81 | SNCA (0.69) | CYP1A2CYP2C19ALDH1A1SNCATSHR | |
| SCHEMBL8374035 | 0.81 | SNCA (0.56) | CYP1A2CYP2C19ALDH1A1SNCAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3951661-A | Silver halide emulsion containing an arylphosphonium salt as antifoggant | KONISHIROKU PHOTO INDUSTRY CO. (JA) | 1976-04-20 | — | — | US | claimed |
| US-9409859-B2 | Substituted diphenyl derivatives | CREATIVE THERAPEUTICS GMBH (DE) | 2016-08-09 | — | — | US | disclosed |
| US-20140005149-A1 | Substituted diphenyl derivatives | CREATIVE THERAPEUTICS GMBH (DE) | 2014-01-02 | — | — | US | disclosed |
| WO-2012130850-A1 | TISSUE TARGETING BY MEANS OF ONCOCIDAL BRIDGED DIPHENYL DERIVATIVES FOR THE SELECTIVE TREATMENT OF SEXUAL ORGAN TUMORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-04 | — | — | WO | disclosed |
| US-20070099876-A1 | Target directed chemotherapy of tumours of the sexual organs | TRIN GMBH (CH) | 2007-05-03 | — | — | US | disclosed |
| EP-0800506-B1 | SOLVENTLESS PROCESS FOR MAKING 2,6-DIFLUOROBENZONITRILE | DOW AGROSCIENCES LLC (US) | 1999-12-22 | — | — | EP | disclosed |
| US-5776718-A | Reversible protease inhibitors | ARRIS PHARMACEUTICAL CORPORATION (US) | 1998-07-07 | — | — | US | disclosed |
| CN-1174546-A | Solventless process for making 2, 6 -difluorobenzonitrile | DOWELANCO (US) | 1998-02-25 | — | — | CN | disclosed |
| US-5502235-A | FLUORINATON OF 2,6-DICHLOROBENZONITRILE | DOWELANCO (US) | 1996-03-26 | — | — | US | disclosed |
| EP-0150433-B1 | PROCESS FOR THE PREPARATION OF INSATURATED KETONES | BASF Aktiengesellschaft (DE) | 1986-12-30 | — | — | EP | disclosed |
| EP-0150433-A2 | Process for the preparation of insaturated ketones | BASF Aktiengesellschaft (DE) | 1985-08-07 | — | — | EP | disclosed |
| US-4150105-A | 3-Ketosteroid antigenic conjugates, their preparation, antibodies and use | BIOLOGICAL DEVELOPMENTS, INC. (US) | 1979-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099876-A1 | Target directed chemotherapy of tumours of the sexual organs | GPER1, SHBG, GNRHR | CYP1A2 746/4885CYP2C19 847/4885ALDH1A1 769/4885 |
| US-20140005149-A1 | Substituted diphenyl derivatives | DPYD, VHL, TP53 | CYP1A2 1582/4885CYP2C19 2343/4885ALDH1A1 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.